Published in Transplantation on June 27, 2004
Spectrum of cancer risk among US solid organ transplant recipients. JAMA (2011) 4.99
Effectiveness of a combination therapy using calcineurin inhibitor and mTOR inhibitor in preventing allograft rejection and post-transplantation renal cancer progression. Cancer Lett (2012) 2.05
Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol (2010) 1.45
The clinical utility of FDG PET/CT among solid organ transplant recipients suspected of malignancy or infection. Eur J Nucl Med Mol Imaging (2016) 1.39
Roles of the immune system in skin cancer. Br J Dermatol (2011) 1.12
Overexpression of vascular endothelial growth factor and the development of post-transplantation cancer. Cancer Res (2008) 1.11
Cancer in the transplant recipient. Cold Spring Harb Perspect Med (2013) 1.06
The association between chronic renal failure and renal cell carcinoma may differ between black and white Americans. Cancer Causes Control (2012) 1.04
Preventing Allograft Rejection by Targeting Immune Metabolism. Cell Rep (2015) 1.02
Calcineurin inhibitors modulate CXCR3 splice variant expression and mediate renal cancer progression. J Am Soc Nephrol (2008) 1.00
Altered VEGF mRNA stability following treatments with immunosuppressive agents: implications for cancer development. J Biol Chem (2010) 0.99
Malignancy after renal transplantation: the role of immunosuppression. Nat Rev Nephrol (2010) 0.98
Calcineurin inhibitor-induced and Ras-mediated overexpression of VEGF in renal cancer cells involves mTOR through the regulation of PRAS40. PLoS One (2011) 0.93
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett (2013) 0.88
Increased Tc22 and Treg/CD8 ratio contribute to aggressive growth of transplant associated squamous cell carcinoma. PLoS One (2013) 0.85
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies. Med Mol Morphol (2011) 0.84
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype. Nephrol Dial Transplant (2012) 0.83
Toxicities of immunosuppressive treatment of autoimmune neurologic diseases. Curr Neuropharmacol (2011) 0.82
Post-transplantation malignancies: here today, gone tomorrow? Nat Rev Clin Oncol (2015) 0.81
Sirolimus for visceral and cutaneous Kaposi's sarcoma in a renal-transplant recipient. Clin Exp Nephrol (2007) 0.81
Renal transplantation today. Langenbecks Arch Surg (2008) 0.80
Antineoplastic effects of mammalian target of rapamycine inhibitors. World J Transplant (2012) 0.80
Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease. Expert Rev Clin Immunol (2010) 0.80
Liver transplantation for hepatocellular carcinoma on cirrhosis: strategies to avoid tumor recurrence. World J Gastroenterol (2011) 0.79
The role of everolimus in liver transplantation. Clin Exp Gastroenterol (2014) 0.79
Incidence, risk factors and outcomes of de novo malignancies post liver transplantation. World J Hepatol (2016) 0.78
A second delivery after heart transplantation - a case study. Kardiochir Torakochirurgia Pol (2014) 0.78
Sebaceous carcinoma of the suprapubic area in a liver transplant recipient. Ann Dermatol (2014) 0.77
Impact of non-oncological factors on tumor recurrence after liver transplantation in hepatocellular carcinoma patients. World J Gastroenterol (2016) 0.77
Cyclosporin-A associated malignancy. Clin Ophthalmol (2007) 0.76
Incidence, risk factors and outcome of de novo tumors in liver transplant recipients focusing on alcoholic cirrhosis. World J Hepatol (2015) 0.76
Use of photodynamic therapy for treatment of actinic keratoses in organ transplant recipients. Biomed Res Int (2012) 0.76
Endometrial polyps in female allograft recipients with abnormal bleedings. Prz Menopauzalny (2014) 0.75
Living donor liver transplantation for hepatocellular carcinoma in Seoul National University. Hepatobiliary Surg Nutr (2016) 0.75
Human Papillomavirus in Kidney Transplant Recipients. Semin Nephrol (2016) 0.75
Effect of mycophenolate mofetil plus adriamycin on HepG-2 cells. World J Hepatol (2010) 0.75
Risk of Renal Cell Carcinoma Among Kidney Transplant Recipients in the United States. Am J Transplant (2016) 0.75
Everolimus for compassionate use in multiple Basal cell carcinomas. Case Rep Dermatol Med (2013) 0.75
Kaposi sarcoma in an patient with atopic dermatitis treated with ciclosporin. BMJ Case Rep (2013) 0.75
A Surgical Perspective on Targeted Therapy of Hepatocellular Carcinoma. Diseases (2015) 0.75
Invasive squamous cell bladder cancer of the ureterovesical junction in a renal transplant patient: a case report. J Surg Case Rep (2017) 0.75
Risk of thyroid cancer among solid organ transplant recipients. Am J Transplant (2017) 0.75
Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med (2002) 7.06
Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA (2009) 3.83
Acute mesenteric ischemia: a vascular emergency. Dtsch Arztebl Int (2012) 2.70
Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol (2010) 2.66
Combined targeted treatment to eliminate tumorigenic cancer stem cells in human pancreatic cancer. Gastroenterology (2009) 2.64
Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem Cell Biol (2008) 2.39
Temporary intraoperative porto-caval shunt: useless or beneficial in piggy back liver transplantation? Transpl Int (2012) 2.17
Loss of liver transplant surgeons into alternate career paths. Transpl Int (2014) 2.04
The German hospital malnutrition study. Clin Nutr (2006) 1.93
Interleukin 21 controls tumour growth and tumour immunosurveillance in colitis-associated tumorigenesis in mice. Gut (2011) 1.84
Evaluation of clinical safety and beneficial effects of a fish oil containing lipid emulsion (Lipoplus, MLF541): data from a prospective, randomized, multicenter trial. Crit Care Med (2007) 1.80
Overture for growth hormone: requiem for interleukin-6? Crit Care Med (2007) 1.69
Induction of IL-13 triggers TGF-beta1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J Immunol (2007) 1.69
Endoscopic vacuum-assisted closure of anastomotic leakage following anterior resection of the rectum: a new method. Surg Endosc (2007) 1.68
Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Transplantation (2006) 1.64
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57
IL-13 signaling via IL-13R alpha2 induces major downstream fibrogenic factors mediating fibrosis in chronic TNBS colitis. Gastroenterology (2008) 1.51
Shedding light on the elusive role of endothelial cells in cytomegalovirus dissemination. PLoS Pathog (2011) 1.51
Tumour nephrectomy with vena cava thrombus. BJU Int (2005) 1.43
High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol (2010) 1.42
The challenge of pancreatic anastomosis. Langenbecks Arch Surg (2008) 1.41
Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation (2004) 1.40
Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis. Cancer Metastasis Rev (2007) 1.38
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer. Clin Cancer Res (2008) 1.35
Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg (2005) 1.35
EFEMP1 expression promotes in vivo tumor growth in human pancreatic adenocarcinoma. Mol Cancer Res (2009) 1.33
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer (2007) 1.30
Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther (2007) 1.29
Inhibition of SRC tyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice. Clin Cancer Res (2004) 1.28
Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res (2013) 1.27
Targeting FGFR/PDGFR/VEGFR impairs tumor growth, angiogenesis, and metastasis by effects on tumor cells, endothelial cells, and pericytes in pancreatic cancer. Mol Cancer Ther (2011) 1.26
Restoration of tumor immunosurveillance via targeting of interleukin-13 receptor-alpha 2. Cancer Res (2008) 1.26
Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol (2011) 1.25
Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest (2011) 1.25
A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int (2008) 1.24
Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer (2005) 1.22
Multipotent mesenchymal stem cells acquire a lymphendothelial phenotype and enhance lymphatic regeneration in vivo. Circulation (2008) 1.22
Insulin attenuates the systemic inflammatory response to thermal trauma. Mol Med (2002) 1.22
Prothrombin complex concentrate in surgical patients: retrospective evaluation of vitamin K antagonist reversal and treatment of severe bleeding. Crit Care (2009) 1.21
Antiangiogenetic therapy with pioglitazone, rofecoxib, and metronomic trofosfamide in patients with advanced malignant vascular tumors. Cancer (2003) 1.20
GFP-transfected tumor cells are useful in examining early metastasis in vivo, but immune reaction precludes long-term tumor development studies in immunocompetent mice. Clin Exp Metastasis (2003) 1.19
Vascular endothelial growth factor in esophageal cancer. J Surg Oncol (2004) 1.19
The prognostic value of lymph node ratio in a population-based collective of colorectal cancer patients. Ann Surg (2010) 1.18
Estimation of liver size for liver transplantation: the impact of age and gender. Liver Transpl (2004) 1.18
Rapamycin induces tumor-specific thrombosis via tissue factor in the presence of VEGF. Blood (2005) 1.17
Cancer stem cells: how can we target them? Curr Med Chem (2008) 1.17
Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int (2008) 1.17
Comparison of laparoscopic vs. open access surgery in patients with rectal cancer: a prospective analysis. Dis Colon Rectum (2008) 1.17
Toward MSC in solid organ transplantation: 2008 position paper of the MISOT study group. Transplantation (2009) 1.16
Determinants of morbidity and survival after elective non-curative resection of stage IV colon and rectal cancer. Int J Colorectal Dis (2009) 1.16
Charitable State-Controlled Foundation Human Tissue and Cell Research: Ethic and Legal Aspects in the Supply of Surgically Removed Human Tissue For Research in the Academic and Commercial Sector in Germany. Cell Tissue Bank (2003) 1.16
EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells. Biol Chem (2009) 1.15
IFN-γ-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther (2012) 1.14
Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation. BMC Gastroenterol (2012) 1.13
Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition. BMC Cancer (2010) 1.12
Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer. Transpl Int (2005) 1.11
Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol (2008) 1.10
Inhibition of insulin-like growth factor-I receptor (IGF-IR) using NVP-AEW541, a small molecule kinase inhibitor, reduces orthotopic pancreatic cancer growth and angiogenesis. Eur J Cancer (2008) 1.10
Pancreatic cancer stem cells: new understanding of tumorigenesis, clinical implications. Langenbecks Arch Surg (2009) 1.10
The intrinsic renal compartment syndrome: new perspectives in kidney transplantation. Transplantation (2010) 1.10
Dose-dependent effects of sirolimus on mTOR signaling and polycystic kidney disease. J Am Soc Nephrol (2012) 1.10
Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann Surg (2009) 1.08
Does surgical resection of pulmonary metastases of head and neck cancer improve survival? Ann Surg Oncol (2008) 1.08
Intravital microscopy of tumor angiogenesis and regression in the dorsal skin fold chamber: mechanistic insights and preclinical testing of therapeutic strategies. Clin Exp Metastasis (2009) 1.08
Outcome of laparoscopic surgery for rectal cancer in 101 patients. Dis Colon Rectum (2003) 1.07
Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int (2011) 1.07
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Cancer stem cells and angiogenesis. Int J Dev Biol (2011) 1.06
Insulin treatment improves hepatic morphology and function through modulation of hepatic signals after severe trauma. Ann Surg (2004) 1.05
Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res (2004) 1.02
Mesenchymal stem cells can affect solid organ allograft survival. Transplantation (2009) 1.01
Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res (2004) 1.01
Ephrin-B2 overexpression enhances integrin-mediated ECM-attachment and migration of B16 melanoma cells. Int J Oncol (2005) 0.99
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Genetically engineered stem cells for therapeutic gene delivery. Curr Gene Ther (2007) 0.99
Procedures for ethical review for clinical trials within the EU. BMJ (2009) 0.99
Beneficial effects of ischemic preconditioning in patients undergoing hepatectomy: the role of neutrophils. Arch Surg (2005) 0.98
Fast-track rehabilitation in elective colorectal surgery patients: a prospective clinical and immunological single-centre study. ANZ J Surg (2007) 0.97
Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation--a phase I study (MISOT-I). J Transl Med (2011) 0.97
Mesenchymal stem cell-based tumor-targeted gene therapy in gastrointestinal cancer. Stem Cells Dev (2012) 0.97
Blocking MAdCAM-1 in vivo reduces leukocyte extravasation and reverses chronic inflammation in experimental colitis. Int J Colorectal Dis (2005) 0.97
Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J Hepatol (2003) 0.97
Mesenchymal stem cells as immunomodulators after liver transplantation. Liver Transpl (2009) 0.97